Article · Wikipedia archive · Last revised Jun 12, 2026

CMLD-2

CMLD-2 is an experimental drug which acts as an inhibitor of the RNA-binding HuR protein. Elevated levels of HuR are found in many forms of cancer, and CMLD-2 is being researched for potential applications in cancer treatment. It also has anti-inflammatory effects, and may also be useful for the treatment of neuropathic pain, as well as asthma, and Hepatitis B.

Last revised
Jun 12, 2026
Read time
≈ 2 min
Length
391 w
Citations
8
Source
Wikipedia ↗
CMLD-2
Identifiers
  • 5,7-dimethoxy-8-[1-(4-methoxyphenyl)-3-oxo-3-pyrrolidin-1-ylpropyl]-4-phenylchromen-2-one
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC31H31NO6
Molar mass513.590 g·mol−1
3D model (JSmol)
  • COC1=CC=C(C=C1)C(CC(=O)N2CCCC2)C3=C(C=C(C4=C3OC(=O)C=C4C5=CC=CC=C5)OC)OC
  • InChI=1S/C31H31NO6/c1-35-22-13-11-21(12-14-22)23(17-27(33)32-15-7-8-16-32)29-25(36-2)19-26(37-3)30-24(18-28(34)38-31(29)30)20-9-5-4-6-10-20/h4-6,9-14,18-19,23H,7-8,15-17H2,1-3H3
  • Key:PROGRNRRJJYCNX-UHFFFAOYSA-N

CMLD-2 is an experimental drug which acts as an inhibitor of the RNA-binding HuR protein. Elevated levels of HuR are found in many forms of cancer, and CMLD-2 is being researched for potential applications in cancer treatment.1234 It also has anti-inflammatory effects, and may also be useful for the treatment of neuropathic pain,56 as well as asthma,7 and Hepatitis B.8

See also

See also

References

References

  1. Muralidharan R, Mehta M, Ahmed R, Roy S, Xu L, Aubé J, et al. (August 2017). "HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells". Scientific Reports. 7 (1) 9694. Bibcode:2017NatSR...7.9694M. doi:10.1038/s41598-017-07787-4. PMC 5577245. PMID 28855578.
  2. Allegri L, Baldan F, Roy S, Aubé J, Russo D, Filetti S, et al. (May 2019). "The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells". Scientific Reports. 9 (1) 7374. Bibcode:2019NatSR...9.7374A. doi:10.1038/s41598-019-43894-0. PMC 6517587. PMID 31089242.
  3. Chaudhary S, Appadurai MI, Maurya SK, Nallasamy P, Marimuthu S, Shah A, et al. (March 2023). "MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR". Breast Cancer Research. 25 (1) 25. doi:10.1186/s13058-023-01630-7. PMC 10012760. PMID 36918912.
  4. Jia MY, Wu C, Fu Z, Xu WB, Liu J, Wu CY, et al. (March 2025). "Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma". Acta Pharmacologica Sinica. 46 (8): 2296–2309. doi:10.1038/s41401-025-01529-3. PMC 12274554. PMID 40133626.
  5. Kunder N, de la Peña JB, Lou TF, Chase R, Suresh P, Lawson J, et al. (December 2022). "The RNA-Binding Protein HuR Is Integral to the Function of Nociceptors in Mice and Humans". The Journal of Neuroscience. 42 (49): 9129–9141. doi:10.1523/JNEUROSCI.1630-22.2022. PMC 9761683. PMID 36270801.
  6. Zhang J, Xu J, Li S, Chen W, Wu Y (November 2023). "Electroacupuncture Relieves HuR/KLF9-Mediated Inflammation to Enhance Neurological Repair after Spinal Cord Injury". eNeuro. 10 (11). doi:10.1523/ENEURO.0190-23.2023. PMC 10668228. PMID 37940560.
  7. Fattahi F, Ellis JS, Sylvester M, Bahleda K, Hietanen S, Correa L, et al. (January 2022). "HuR-Targeted Inhibition Impairs Th2 Proinflammatory Responses in Asthmatic CD4+ T Cells". Journal of Immunology. 208 (1): 38–48. doi:10.4049/jimmunol.2100635. PMID 34862257.
  8. Zheng Y, Wang M, Yin J, Duan Y, Wu C, Xu Z, et al. (February 2024). "Hepatitis B virus RNAs co-opt ELAVL1 for stabilization and CRM1-dependent nuclear export". PLOS Pathogens. 20 (2) e1011999. doi:10.1371/journal.ppat.1011999. PMC 10866535. PMID 38306394.